Self-control impaired in Type 2 diabetics, research suggests
NEW YORK Poor impulse control in patients with Type 2 diabetes may be caused by neurological changes, a new study published in BioPsychoSocial Medicine suggested.
In a small study study, Hiroaki Kumano, from Waseda University, Japan, worked with a team of researchers to assess response inhibition, a measure of self-control, in 27 patients with Type 2 diabetes and 27 healthy controls.
In order to gauge the patients’ ability to resist such impulsive behavior, the researchers used a test in which participants had to quickly press a button in response to the correct signal on a computer screen, while pressing the button in response to the wrong symbol counted against their score. They found that patients with diabetes performed significantly worse at the test, suggesting that they struggled to control the impulse to press the button.
Other results showed that the inhibitory failure observed in diabetic patients was mainly explained by cognitive impairment of impulsivity control, rather than by deficits in motor performance, error monitoring and adjustment.
“Patients with Type 2 diabetes are required to make strict daily decisions; for example, they should resist the temptation of high-fat, high-calorie food, which is frequently cued by specific people, places and events. Appropriate behavior modification thus depends on the patient’s ability to inhibit impulsive thoughts and actions cued by these environmental stimuli,” Kumano said. “This suggests the possibility that the neuropsychological deficits in response inhibition may contribute to the behavioral problems leading to chronic lifestyle-related diseases, such as Type 2 diabetes.”
Biovail, Alexza develop inhaled mental health treatment
MOUNTAIN VIEW, Calif. An inhaled mental health drug could appear on the market in the near future under a collaboration announced Wednesday by Biovail Corp. and Alexza Pharmaceuticals.
Biovail subsidiary Biovail Labs International SRL and Alexza said they would work together to develop and commercialize AZ-004 (loxapine) in the United States and Canada. The drug is based on Alexza’s proprietary Staccato technology and is an inhaled drug designed to treat agitation in patients with bipolar disorder and schizophrenia. Alexza submitted an approval application for the drug to the Food and Drug Administration in December 2009.
Under the terms of the deal, Biovail will pay Alexza $40 million upfront and up to $90 million in milestone payments, if the drug is approved, as well as royalty payments of 10% to 25%.
“We are very excited to be partnering our lead program with Biovail,” Alexza president and CEO Thomas King said in a statement. “Their key strategic focus and their [central nervous system] commercial plans match our view of an ideal partner for AZ-004. We believe that AZ-004, if approved, has the potential to change the treatment practices for acute agitation, as the only product able to meet both the patients’ desire for quickly and comfortably gaining control of their agitation and the clinicians’ goal of rapidly and reliably calming an agitated patient.”
Novartis to develop, market hepatitis C drug
BASEL, Switzerland Novartis has gained exclusive rights to develop and market a hepatitis C drug that is the first of its kind, the Swiss drug maker announced Tuesday.
Novartis acquired control of Debio 025 (alisporivir) from Debiopharm Group. The drug is the first of a drug class known as cyclophilin inhibitors, which target host proteins involved in the growth of the virus. The drug is currently in phase 2b clinical trials.
Under the terms of the agreement, Novartis will pay unspecified upfront and milestone payments to Debiopharm, as well as royalties on sales, in exchange for the exclusive right to develop and market the drug worldwide, except in Japan.
“Hepatitis C is sometimes referred to as a ‘silent epidemic’ because the virus can lie dormant in the body for years or even decades before the symptoms become apparent,” Novartis Pharmaceuticals Division CEO David Epstein said. “Novartis is dedicated to developing medicines that will reduce the impact of this disease on patients, and we believe that Debio 025 could prove an important step forward by significantly enhancing the efficacy of existing therapy that forms the standard of care for hepatitis C.”